Meta-analyses of therapies for postmenopausal osteoporosis

Endocrine Reviews

Volumn 23, Issue 4, 2002, Pages 496-507

  Guyatt, Gordon ^a   Adachi, Jonathan ^b,c,d   Favus, Murray ^e   Griffith, Lauren ^a   McGowan, Jessie ^a   Robinson, Vivian ^a   Rosen, Clifford ^f  

^a MCMASTER UNIVERSITY   (Canada)

^b QUEEN S UNIVERSITY   (Canada)

^c UNIVERSITY OF OTTAWA   (Canada)

^d UNIVERSITY OF OTTAWA   (Canada)

^e UNIVERSITY OF CHICAGO   (United States)

^f ST JOSEPH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; ETIDRONIC ACID; RALOXIFENE; RISEDRONIC ACID; VITAMIN D;

ACCURACY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; EVIDENCE BASED MEDICINE; FEMALE; FOLLOW UP; HORMONE SUBSTITUTION; HUMAN; MEDICAL DECISION MAKING; META ANALYSIS; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REPRODUCIBILITY; REVIEW; VALIDATION PROCESS; VERTEBRA FRACTURE;

FEMALE; HUMAN; OSTEOPOROSIS, POSTMENOPAUSAL; RANDOMIZED CONTROLLED TRIALS;

EID: 0036677767     PISSN: 0163769X     EISSN: None     Source Type: Journal    
DOI: 10.1210/er.2001-1002     Document Type: Review

References (45)

1. Prophylaxis and treatment of osteoporosis
2. Diagnosis, prophylaxis, and treatment of osteoporosis
3. The diagnosis of osteoporosis
4. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis
5. Use of T-scores to establish comparable diagnostic categories for bone densitometers
6. Risk of mortality following clinical fractures
7. Population-based study of survival after osteoporotic fractures
8. Mortality following fractures in older women. The study of osteoporotic fractures
9. Lifetime risks of hip, Colles' or vertebral fracture rate and coronary heart disease among white postmenopausal women
10. The science of reviewing research
11. The medical review article revisited: Has the science improved?
12. Cumulative meta-analysis of therapeutic trials for myocardial infarction
13. A comparison of results of meta-analyses of randomized control trials and recommendations of clinical experts. Treatment for myocardial infarction
14. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in metaanalyses?
15. Estrogen replacement therapy and coronary heart disease: A quantitative assessment of the epidemiologic evidence
16. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women
17. Systematic reviews: Synthesis of best evidence for clinical decisions
18. Selecting and appraising studies for a systematic review
19. Assessing the quality of reports of randomized clinical trials: Is blinding necessary?
20. Empirical evidence of bias; dimensions of methodological quality associated with estimates of treatment effects in controlled trials
21. Physician interpretations and textbook definitions of blinding terminology in randomized controlled trials
22. Quantitative synthesis in systematic reviews
23. A consumer's guide to subgroup analysis
24. Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials
25. Which fractures are associated with low appendicular bone mass in elderly women?
26. Developing optimal search strategies for detecting clinically sound strategies in MEDLINE
27. Identifying relevant studies for systematic reviews
28. Should unpublished studies be included in meta-analyses? Current convictions and controversies
29. The existence of publication bias and risk factors for its occurrence
30. Factors influencing publication of research results
31. Publication bias: A problem in interpreting medical data
32. Impact of covert duplicate publication on meta-analysis: A case study
33. Improving the quality of reports of meta-analyses of randomised controlled trials: The QUOROM statement. Quality of reporting of meta-analyses
34. Assessing the quality of reports of systematic reviews: The QUOROM statement compared to other tools
35. Measuring nominal scale agreement among many raters
36. Bias in treatment assignment in controlled clinical trials
37. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures
38. The statistical basis of meta-analysis
39. Meta-analysis: State-of-the-science
40. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene
41. Treatment of established postmenopausal osteoporosis with raloxifene; a randomized trial
42. A meta-analysis of etidronate for postmenopausal osteoporosis
43. Users' guides to the medical literature. VI. How to use an overview